Drug delivery systems for cancer drugs

Bibliography

• SUZUKI H, SUGIYAMA Y: Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur.j Mann. Sci. (2000) 12(1):3–12.
   Google Scholar
• ••Review of the significant role of the smallintestine in reducing oral bioavailability of drugs by means of metabolic enzymes and efflux transporters.
   Google Scholar
• SPARREBOOM A, NOOTER K: Does P-glycoprotein play a role in anticancer drug pharmacokinetics? Drug Resist. Update (2000) 3 (6):357–363.
   Google Scholar
• •Explanation of the pharmacokinetic interference of P-gp inhibitors with anticancer drugs.
   Google Scholar
• GOTTESMAN MM, FOJO TG, BATES SE: Multi-drug resistance in cancer: role of ATP-dependant transporters. Nat. Rev Cancer (2002):2:48–58.
   PubMed Web of Science ®Google Scholar
• ••Quick and efficacious review explainingfunctionalities of ATP-dependent transporters and their impact on cancer therapy.
   Google Scholar
• MOUNTFIELD RJ, SENEPIN S, SCHLEIMER M, WALTER I, BITTNER B: Potential inhibitory effects of formulation ingredients on intestinal cytochrome P450. Int. .1. Pliann. (2000) 211:89–92.
   PubMed Web of Science ®Google Scholar
• •One of the first papers showing how common pharmaceutical excipients can inhibit the metabolic activities of drugs on CYP3A in the intestinal tract.
   Google Scholar
• BALUOM M, FRIEDMAN M, RUBINSTEIN A: Improved intestinal absorption of sulpiride in rats with synchronized oral delivery systems. J. Control Release (2001) 70:139–147.
   PubMed Web of Science ®Google Scholar
• •Effects of verapamil and quinidine on increasing the oral availability of drugs that are P-gp substrates.
   Google Scholar
• CHAN YL, CHOU MH, LIN MF, CHEN CF, TSAI TH: Effect of cyclosporine, a P-glycoprotein inhibitor, on the pharmacokinetics of cefepime in rat blood and brain: a microdialysis study. Life Sci. (2001) 69(2):191–199.
   PubMed Web of Science ®Google Scholar
• •Clinical application of cydosporin as a P-gp inhibitor.
   Google Scholar
• SHARMA S, WHITE D, IMONDI AR, PLACKE ME, VAIL DM, KRIS MG: Development of inhalational agents for oncological use. J. Clin. Oncol (2001) 19(6):1839–1847. Review of the rationale of drug delivery by the inhalational route for oncologic drugs, including the technical challenges to be faced.
   Google Scholar
• SHARMA S, WHITE D, KRIS M et al.: A multicenter Phase I clinical and pharmacologic study of inhaled doxorubicin (Resmycin) in adults with advanced solid tumors affecting the lungs. ASCO Ann. Meeting, Orlando, USA (2002) 1204.
   Google Scholar
• •Outcome of early clinical studies on doxorubicin by inhalation showing no local toxicity or promising findings as far as therapeutic dose reduction is concerned.
   Google Scholar
• BRIGGER I, DUBERNET C, COUVREUR P: Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deity. Rev (2002) 54(5):631–651.
   PubMed Web of Science ®Google Scholar
• ••State-of-the-art review dealing with long- circulating nanoparticulates and tumour targeting.
   Google Scholar
• ALLEN C, DOS SANTOS N, GALLAGHER R et al.: Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci. Rep. (2002) 22 (2):225–250.
   PubMed Web of Science ®Google Scholar
• •Role of poly(ethylene) glycol on liposomal carrier surface.
   Google Scholar
• MAMOT C, DRUMMOND DC, HONG K, KIRPOTIN DB, PARK JW: Liposome-based approaches to overcome anticancer drug resistance. Drug Resistance Updates (in press).
   Google Scholar
• ••Formulation strategies for overcomingdrug resistance using modified liposomes.
   Google Scholar
• MULLER RH, MADER K, GOHLA S: Solid lipid nanoparticles for controlled drug delivery - a review of the state-of-the-art. Ear: j Pharm. Biopliann. (2000) 50:161–177.
   PubMed Web of Science ®Google Scholar
• ••Updated review on the state-of-the-art in the SLN field with manufacturing methods and particular emphasis on drug incorporation, loading capacity and drug release mechanisms.
   Google Scholar
• MEHNERT W, MADER K: Solid lipid nanoparticles, production, characterization and applications. Adv. Drug Deity. Rev (2001) 41:165–196.
   Google Scholar
• •Overview on excipient selection for SLN and on physicochemical stability aspects of formulations.
   Google Scholar
• HEURTAULT B, SAULNIER P, PECH B, PROUST JE, BENOIT JP: Physico-chemical stability of colloidal lipid particles. Bioniaterials (2003) 24(23):4283–4300.
   PubMed Web of Science ®Google Scholar
• •Optimisation of the stability of lipid nanoparticles.
   Google Scholar
• HOU D, XIE C, HUANG K, ZHU C: The production and characteristics of solid lipid nanoparticles. Biontaterials (2003) 24(10):1781–1785.
   PubMed Web of Science ®Google Scholar
• •Solid lipid nanoparticle characterisation.
   Google Scholar
• RAPOPORT N, PITT WG, SUN H, NELSON JL: Drug delivery in polymeric micelles: from IP vitro to in vivo. I Control. Release (2003) 91(1-2):85–95.
   PubMed Web of Science ®Google Scholar
• •Application of polymeric miceller systems in tumour therapy.
   Google Scholar
• KABANOV AV, BATRAKOVA EV, ALAKHOV VY: Pluronic° block copolymers as novel polymer therapeutics for drug and gene delivery. J. Control. Release (2002) 82(2-3):189–212.
   PubMed Web of Science ®Google Scholar
• •Review of applications of block copolymers as drug solubilisers and their effect in improving metabolic stability and circulation time of several active drugs.
   Google Scholar
• ANDERSON JM, SHIVE MS: Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rey (1997) 28(1):5–24.
   PubMed Web of Science ®Google Scholar
• •An old but still relevant review on the fundamental understanding of the in vivo biodegradation phenomenon of biodegradable microspheres.
   Google Scholar
• SCHWACH G, OUDRY N, DELHOMME S, LUCK M, LINDNER H, GURNY R: Biodegradable microparticles for sustained release of a new GnRH antagonist - part I: screening commercial PLGA and formulation technologies. Eur: Phann. Biophann. (2003) 56:327–336.
   PubMed Web of Science ®Google Scholar
• TIPTON AJ, DUNN RL: ha situ gelling systems - sustained released injectable products: Interphann. Press (2000):241–278.
   Google Scholar
• •Extensive review on biodegradable depot systems that are formed in situ as the formulation is injected in the body.
   Google Scholar